...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Gut and Liver >Potential Efficacy of Pegylated Interferon-α and a Nucleos(t)ide Analogue as Combination Therapy for HBeAg-Positive Chronic Hepatitis B
【24h】

Potential Efficacy of Pegylated Interferon-α and a Nucleos(t)ide Analogue as Combination Therapy for HBeAg-Positive Chronic Hepatitis B

机译：聚乙二醇化干扰素-α和核苷类似物作为联合治疗HBeAg阳性慢性乙型肝炎的潜在疗效

获取原文
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background/AimsDespite the potent suppression of the hepatitis B virus with modern antiviral agents, only a minority of HBeAg-positive patients achieve hepatitis B e antigen seroconversion. We aimed to explore the potential efficacy of combination therapy consisting of pegylated interferon (p-IFN) and an oral antiviral agent in patients with HBeAg-positive chronic hepatitis B.MethodsThe treatment protocol consisted of p-IFN-α-2a at 180 μg/wk for 48 weeks, with either entecavir or tenofovir added 8 weeks after the initiation of p-IFN and continued for at least 6 months after HBe seroconversion was achieved.ResultsTo date, 10 patients have been treated under the protocol (eight adults, mean age 36±8 years; two adolescents, aged 12 and 16 years). All eight adult patients experienced loss of HBeAg at a mean of 72.3±66.9 weeks, including six patients who also developed anti-HBe and one patient who had HBs seroconversion. Although both adolescents remain on therapy, one adolescent had HBs seroconversion without HBe seroconversion. A total of nine of our 10 patients experienced a favorable serological transition.ConclusionsThe combination of p-IFN and a modern oral antiviral agent may be more effective than monotherapy with either class of agent in the treatment of HBeAg-positive chronic hepatitis B patients.
机译：背景/目的尽管用现代抗病毒剂有效抑制了乙型肝炎病毒，但只有少数HBeAg阳性患者实现了乙型肝炎e抗原血清转化。我们旨在探讨由聚乙二醇干扰素（p-IFN）和口服抗病毒药联合治疗对HBeAg阳性慢性乙型肝炎患者的潜在疗效。方法治疗方案由p-IFN-α-2a组成，剂量为180μg/连续48周，在开始p-IFN后8周加入恩替卡韦或替诺福韦，并在达到HBe血清转化后持续至少6个月。结果迄今为止，已按照该方案治疗了10例患者（8名成年人，平均年龄36±8岁;两个青少年，年龄分别为12和16岁。所有八名成年患者平均经历72.3±66.9周的HBeAg丧失，包括六名也产生了抗HBe的患者和一名HBs血清转化的患者。尽管两个青少年都接受治疗，但一个青少年的HBs血清转化而无HBe血清转化。我们的10例患者中有9例经历了良好的血清学转变。结论p-IFN与现代口服抗病毒药的联合治疗可能比单一疗法联合任何一种药物治疗HBeAg阳性慢性乙型肝炎患者更有效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号